Johnson & Johnson recently held their second-quarter 2025 earnings conference call, providing insights into the company's performance and future outlook. Key attendees included Darren Snellgrove, Vice President of Investor Relations, Joaquin Duato, Chairman of the Board, Chief Executive Officer, and Joseph Wolk, Chief Financial Officer. During the call, management highlighted the strength of their diversified business and projected elevated growth in the latter half of the year. Significant milestones are anticipated in areas such as lung and bladder cancer, major depressive disorder, psoriasis, surgery, and cardiovascular. These advancements are expected to "extend and improve lives in transformative ways and deliver significant value to patients and shareholders," as noted by a member of the management team. The full transcript can be accessed through the link below.